<DOC>
	<DOCNO>NCT00006164</DOCNO>
	<brief_summary>The HALT-C Trial National Institute Diabetes Digestive Kidney Diseases sponsor , randomize clinical trial long-term use Peginterferon alfa-2a ( pegylated interferon ) patient fail respond prior interferon treatment . All patient enter trial treat 6 month Peginterferon alfa-2a Ribavirin . Patients respond 6 month treatment continue treat additional 6 month . Patients respond treatment eligible long-term maintenance phase study patient randomly select treated Peginterferon alfa-2a discontinue treatment 3.5 year . Patients arm study follow closely quarterly study visit . The combination peginterferon plus ribavirin recently approve FDA treatment chronic HCV . Patients remain HCV-RNA positive treat least 6 month peginterferon ribavirin outside study may eligible directly enter randomize portion HALT-C Trial . The HALT-C study design determine continue interferon long-term several year suppress Hepatitis C virus , prevent progression cirrhosis , prevent liver cancer reduce need liver transplantation .</brief_summary>
	<brief_title>Long Term Interferon Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Age entry least 18 year . Positive Hepatitis C. Previous treatment interferon interferon ribavirin least 3 month . Documented nonresponse treatment interferon . A liver biopsy demonstrate significant liver scarring . No liver disease . No unstable major medical disease condition . No major complication cirrhosis . No recent abuse alcohol illicit drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>liver disease</keyword>
	<keyword>hepatitis c virus</keyword>
	<keyword>antiviral agent</keyword>
	<keyword>cirrhosis</keyword>
</DOC>